Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.

Beck H, Jeske M, Thede K, Stoll F, Flamme I, Akbaba M, Ergüden JK, Karig G, Keldenich J, Oehme F, Militzer HC, Hartung IV, Thuss U.

ChemMedChem. 2018 May 23;13(10):988-1003. doi: 10.1002/cmdc.201700783. Epub 2018 Apr 14.

2.

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.

Flamme I, Ellinghaus P, Urrego D, Krüger T.

PLoS One. 2017 Oct 26;12(10):e0186979. doi: 10.1371/journal.pone.0186979. eCollection 2017.

3.

Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.

Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U.

PLoS One. 2014 Nov 13;9(11):e111838. doi: 10.1371/journal.pone.0111838. eCollection 2014.

4.

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.

Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, Ehrmann A, Summer H, Flamme I, Oehme F, Thierauch K, Michels M, Hess-Stumpp H, Ziegelbauer K.

Cancer Med. 2013 Oct;2(5):611-24. doi: 10.1002/cam4.112. Epub 2013 Aug 20.

5.

PHD4 stimulates tumor angiogenesis in osteosarcoma cells via TGF-α.

Klotzsche-von Ameln A, Prade I, Grosser M, Kettelhake A, Rezaei M, Chavakis T, Flamme I, Wielockx B, Breier G.

Mol Cancer Res. 2013 Nov;11(11):1337-48. doi: 10.1158/1541-7786.MCR-13-0201. Epub 2013 Sep 18.

6.

Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.

Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I, Ozasa H, Itoh Y, Ogasawara D, Komaarashi H, Kato A, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N.

J Med Chem. 2010 Aug 12;53(15):5629-38. doi: 10.1021/jm1003655.

PMID:
20684604
7.

Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors.

Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH, Acker T.

Cancer Res. 2010 Jan 1;70(1):357-66. doi: 10.1158/0008-5472.CAN-09-1876. Epub 2009 Dec 22.

8.

Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide.

Berchner-Pfannschmidt U, Tug S, Trinidad B, Oehme F, Yamac H, Wotzlaw C, Flamme I, Fandrey J.

J Biol Chem. 2008 Nov 14;283(46):31745-53. doi: 10.1074/jbc.M804390200. Epub 2008 Sep 6.

9.

The impact of N-nitrosomelatonin as nitric oxide donor in cell culture experiments.

Berchner-Pfannschmidt U, Tug S, Trinidad B, Becker M, Oehme F, Flamme I, Fandrey J, Kirsch M.

J Pineal Res. 2008 Nov;45(4):489-96. doi: 10.1111/j.1600-079X.2008.00622.x. Epub 2008 Jul 31.

PMID:
18673420
10.

Determination and modulation of prolyl-4-hydroxylase domain oxygen sensor activity.

Wirthner R, Balamurugan K, Stiehl DP, Barth S, Spielmann P, Oehme F, Flamme I, Katschinski DM, Wenger RH, Camenisch G.

Methods Enzymol. 2007;435:43-60.

PMID:
17998048
11.

Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development.

Licht AH, Müller-Holtkamp F, Flamme I, Breier G.

Blood. 2006 Jan 15;107(2):584-90. Epub 2005 Sep 27.

PMID:
16189264
12.

Genetic evidence for a tumor suppressor role of HIF-2alpha.

Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, Riedel J, Elvert G, Flamme I, Maxwell PH, Collen D, Dewerchin M, Jain RK, Plate KH, Carmeliet P.

Cancer Cell. 2005 Aug;8(2):131-41.

13.

Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation.

Martin F, Linden T, Katschinski DM, Oehme F, Flamme I, Mukhopadhyay CK, Eckhardt K, Tröger J, Barth S, Camenisch G, Wenger RH.

Blood. 2005 Jun 15;105(12):4613-9. Epub 2005 Mar 1.

14.

A nonradioactive 96-well plate assay for the detection of hypoxia-inducible factor prolyl hydroxylase activity.

Oehme F, Jonghaus W, Narouz-Ott L, Huetter J, Flamme I.

Anal Biochem. 2004 Jul 1;330(1):74-80.

PMID:
15183764
15.

Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1).

Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, Flamme I.

J Biol Chem. 2003 Feb 28;278(9):7520-30. Epub 2002 Dec 2.

16.

Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors.

Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hütter J, Schramm M, Flamme I.

Biochem Biophys Res Commun. 2002 Aug 16;296(2):343-9.

PMID:
12163023
18.

Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development.

Kappel A, Schlaeger TM, Flamme I, Orkin SH, Risau W, Breier G.

Blood. 2000 Nov 1;96(9):3078-85.

PMID:
11049987
19.

Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds.

Lauer G, Sollberg S, Cole M, Flamme I, Stürzebecher J, Mann K, Krieg T, Eming SA.

J Invest Dermatol. 2000 Jul;115(1):12-8.

20.

mRNA cloning and expression studies of the quail homologue of HIF-2alpha.

Elvert G, Lanz S, Kappel A, Flamme I.

Mech Dev. 1999 Sep;87(1-2):193-7.

22.

Characterization of novel nuclear targeting and apoptosis-inducing domains in FAS associated factor 1.

Fröhlich T, Risau W, Flamme I.

J Cell Sci. 1998 Aug;111 ( Pt 16):2353-63.

24.
25.

Molecular mechanisms of vasculogenesis and embryonic angiogenesis.

Flamme I, Frölich T, Risau W.

J Cell Physiol. 1997 Nov;173(2):206-10. Review. No abstract available.

PMID:
9365523
26.

Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors.

McNagny KM, Pettersson I, Rossi F, Flamme I, Shevchenko A, Mann M, Graf T.

J Cell Biol. 1997 Sep 22;138(6):1395-407.

27.
28.

Flk-1 as a target for tumor growth inhibition.

Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK.

Cancer Res. 1996 Aug 1;56(15):3540-5.

32.

Vasculogenesis.

Risau W, Flamme I.

Annu Rev Cell Dev Biol. 1995;11:73-91. Review.

PMID:
8689573
33.

Induction of vasculogenesis in quail blastodisc-derived embryoid bodies.

Krah K, Mironov V, Risau W, Flamme I.

Dev Biol. 1994 Jul;164(1):123-32.

PMID:
8026617
34.
35.

Induction of vasculogenesis and hematopoiesis in vitro.

Flamme I, Risau W.

Development. 1992 Oct;116(2):435-9.

37.

Two-phase in vitro culture of explanted chick embryos.

Flamme I, Albach K, Müller S, Christ B, Jacob HJ.

Anat Rec. 1991 Mar;229(3):427-33.

PMID:
2024782
39.

Reexpression of alpha-smooth muscle actin isoform in cultured adult rat cardiomyocytes.

Eppenberger-Eberhardt M, Flamme I, Kurer V, Eppenberger HM.

Dev Biol. 1990 Jun;139(2):269-78.

PMID:
2186943
40.
41.

Prolonged and simplified in vitro culture of explanted chick embryos.

Flamme I.

Anat Embryol (Berl). 1987;176(1):45-52.

PMID:
3605649
42.

Supplemental Content

Loading ...
Support Center